STOCK TITAN

Charles Riv Labs Intl Inc Financials

CRL
Source SEC Filings (10-K/10-Q) Updated Sep 27, 2025 Currency USD FYE December

Financial Health Signals

Profitability Growth Leverage Liquidity Cash Flow Returns 40 / 100
Financial Profile 40/100

Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability
28

Charles Riv Labs Intl Inc has an operating margin of 5.6%, meaning the company retains $6 of operating profit per $100 of revenue. This below-average margin results in a low score of 28/100, suggesting thin profitability after operating expenses. This is down from 14.9% the prior year.

Growth
23

Charles Riv Labs Intl Inc's revenue declined 1.9% year-over-year, from $4.1B to $4.0B. This contraction results in a growth score of 23/100.

Leverage
87

Charles Riv Labs Intl Inc carries a low D/E ratio of 0.65, meaning only $0.65 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 87/100, indicating a strong balance sheet with room for future borrowing.

Liquidity
36

Charles Riv Labs Intl Inc's current ratio of 1.41 indicates adequate short-term liquidity, earning a score of 36/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow
62

Charles Riv Labs Intl Inc has a free cash flow margin of 12.4%, earning a moderate score of 62/100. The company generates positive cash flow after capital investments, but with room for improvement.

Returns
3

Charles Riv Labs Intl Inc generates a 0.6% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 3/100. This is down from 13.2% the prior year.

Altman Z-Score Grey Zone
2.22

Charles Riv Labs Intl Inc scores 2.22, placing it in the grey zone between 1.81 and 2.99. The score is driven primarily by a large market capitalization ($7.9B) relative to total liabilities ($4.0B). This signals moderate financial risk that warrants monitoring.

Piotroski F-Score Neutral
6/9

Charles Riv Labs Intl Inc passes 6 of 9 financial strength tests. 3 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Cash-Backed
33.08x

For every $1 of reported earnings, Charles Riv Labs Intl Inc generates $33.08 in operating cash flow ($734.6M OCF vs $22.2M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage At Risk
1.8x

Charles Riv Labs Intl Inc earns $1.8 in operating income for every $1 of interest expense ($227.3M vs $126.3M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

This page shows Charles Riv Labs Intl Inc (CRL) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 17 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Export CSV

Key Financial Metrics

Revenue
$4.0B
YoY-1.9%
5Y CAGR+9.1%
10Y CAGR+12.1%

Charles Riv Labs Intl Inc generated $4.0B in revenue in fiscal year 2024. This represents a decrease of 1.9% from the prior year.

EBITDA
$589.1M
YoY-36.8%
5Y CAGR+1.4%
10Y CAGR+8.0%

Charles Riv Labs Intl Inc's EBITDA was $589.1M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 36.8% from the prior year.

Free Cash Flow
$501.6M
YoY+37.3%
5Y CAGR+8.1%
10Y CAGR+9.9%

Charles Riv Labs Intl Inc generated $501.6M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 37.3% from the prior year.

Net Income
$22.2M
YoY-95.3%
5Y CAGR-38.5%
10Y CAGR-16.0%

Charles Riv Labs Intl Inc reported $22.2M in net income in fiscal year 2024. This represents a decrease of 95.3% from the prior year.

EPS (Diluted)
$0.20
YoY-97.8%
5Y CAGR-47.6%
10Y CAGR-22.8%

Charles Riv Labs Intl Inc earned $0.20 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 97.8% from the prior year.

Cash & Debt
$194.6M
YoY-29.7%
5Y CAGR-3.9%
10Y CAGR+2.0%

Charles Riv Labs Intl Inc held $194.6M in cash against $2.2B in long-term debt as of fiscal year 2024.

Dividends Per Share
N/A
Shares Outstanding
51M
YoY-0.4%
5Y CAGR+0.9%
10Y CAGR+0.8%

Charles Riv Labs Intl Inc had 51M shares outstanding in fiscal year 2024. This represents a decrease of 0.4% from the prior year.

Gross Margin
N/A
Operating Margin
5.6%
YoY-9.3pp
5Y CAGR-7.8pp
10Y CAGR-8.1pp

Charles Riv Labs Intl Inc's operating margin was 5.6% in fiscal year 2024, reflecting core business profitability. This is down 9.3 percentage points from the prior year.

Net Margin
0.5%
YoY-10.9pp
5Y CAGR-9.1pp
10Y CAGR-9.2pp

Charles Riv Labs Intl Inc's net profit margin was 0.5% in fiscal year 2024, showing the share of revenue converted to profit. This is down 10.9 percentage points from the prior year.

Return on Equity
0.6%
YoY-12.6pp
5Y CAGR-14.8pp
10Y CAGR-18.2pp

Charles Riv Labs Intl Inc's ROE was 0.6% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is down 12.6 percentage points from the prior year.

R&D Spending
N/A
Share Buybacks
$119.2M
YoY+393.4%
5Y CAGR+45.8%
10Y CAGR-0.2%

Charles Riv Labs Intl Inc spent $119.2M on share buybacks in fiscal year 2024, returning capital to shareholders by reducing shares outstanding. This represents an increase of 393.4% from the prior year.

Capital Expenditures
$233.0M
YoY-26.9%
5Y CAGR+10.6%
10Y CAGR+15.1%

Charles Riv Labs Intl Inc invested $233.0M in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 26.9% from the prior year.

CRL Income Statement

Metric Q3'25 Q2'25 Q1'25 Q3'24 Q2'24 Q1'24 Q4'23 Q3'23
Revenue $1.0B-2.6% $1.0B+4.9% $984.2M-1.8% $1.0B-2.3% $1.0B+1.4% $1.0B-0.2% $1.0B-1.3% $1.0B
Cost of Revenue N/A N/A N/A $660.7M-1.7% $672.4M+0.9% $666.7M N/A $664.8M
Gross Profit N/A N/A N/A $349.0M-1.3% $353.7M+2.6% $344.8M N/A $361.8M
R&D Expenses N/A N/A N/A N/A N/A N/A N/A N/A
SG&A Expenses $177.6M-7.3% $191.5M+7.7% $177.8M-9.2% $195.7M+15.3% $169.8M-8.9% $186.3M-5.5% $197.1M+11.9% $176.1M
Operating Income $133.8M+33.6% $100.1M+34.1% $74.7M+144.5% -$167.7M-210.6% $151.7M+20.4% $126.0M-5.2% $132.9M-12.3% $151.5M
Interest Expense $25.4M-15.2% $30.0M+7.5% $27.9M-1.2% $28.2M-13.8% $32.8M-6.4% $35.0M+4.3% $33.5M-0.6% $33.7M
Income Tax $31.6M+69.0% $18.7M+85.4% $10.1M+431.8% -$3.0M-112.0% $25.4M+3.5% $24.5M+24.2% $19.8M-20.5% $24.9M
Net Income $54.4M+4.0% $52.3M+105.4% $25.5M+111.9% -$214.5M-328.0% $94.1M+28.9% $73.0M-61.0% $187.1M+114.1% $87.4M
EPS (Diluted) $1.10+3.8% $1.06+112.0% $0.50+112.0% $-4.17-339.7% $1.74+33.8% $1.30-64.2% $3.63+114.8% $1.69

CRL Balance Sheet

Metric Q3'25 Q2'25 Q1'25 Q3'24 Q2'24 Q1'24 Q4'23 Q3'23
Total Assets $7.5B-0.6% $7.6B-0.3% $7.6B+0.7% $7.5B-5.3% $7.9B-2.5% $8.2B-0.5% $8.2B+7.7% $7.6B
Current Assets $1.5B+4.2% $1.5B-2.4% $1.5B+7.4% $1.4B-6.4% $1.5B-10.1% $1.7B+3.7% $1.6B+11.4% $1.4B
Cash & Equivalents $207.1M+13.3% $182.8M-20.3% $229.4M+17.9% $194.6M+8.6% $179.2M-45.2% $327.0M+18.2% $276.8M+76.1% $157.2M
Inventory $302.6M+8.2% $279.6M-3.7% $290.2M+4.2% $278.5M-20.2% $349.1M-3.4% $361.3M-5.0% $380.3M+29.8% $293.0M
Accounts Receivable $734.5M-4.3% $767.6M+1.4% $756.6M+5.0% $720.9M-5.4% $762.2M-3.1% $787.0M+0.8% $780.4M-2.4% $799.3M
Goodwill $2.9B-0.5% $2.9B+2.2% $2.9B+0.9% $2.8B-7.6% $3.1B+0.3% $3.1B-0.8% $3.1B+7.3% $2.9B
Total Liabilities $4.1B-2.4% $4.2B-4.1% $4.3B+8.0% $4.0B-3.7% $4.2B-6.2% $4.4B-1.9% $4.5B+6.6% $4.3B
Current Liabilities $1.1B+3.8% $1.1B+2.8% $1.1B+5.7% $994.1M+4.9% $947.5M-0.8% $954.8M-9.5% $1.1B+6.2% $993.8M
Long-Term Debt $2.2B-6.3% $2.3B-7.1% $2.5B+12.1% $2.2B-7.0% $2.4B-9.4% $2.7B+0.5% $2.6B+5.3% $2.5B
Total Equity $3.4B+1.6% $3.4B+5.0% $3.2B-7.7% $3.5B-7.0% $3.7B+2.3% $3.6B+1.2% $3.6B+8.8% $3.3B
Retained Earnings $1.9B+2.9% $1.9B+2.8% $1.8B+1.4% $1.8B-11.8% $2.1B+4.8% $2.0B+3.8% $1.9B+9.7% $1.7B

CRL Cash Flow Statement

Metric Q3'25 Q2'25 Q1'25 Q3'24 Q2'24 Q1'24 Q4'23 Q3'23
Operating Cash Flow $213.8M+4.5% $204.6M+19.2% $171.7M+7.7% $159.4M-17.7% $193.5M+49.0% $129.9M-41.2% $220.9M+7.5% $205.4M
Capital Expenditures $35.6M+0.8% $35.3M-40.5% $59.3M-21.5% $75.6M+91.5% $39.5M-50.1% $79.1M+1.0% $78.3M+18.8% $65.9M
Free Cash Flow $178.2M+5.3% $169.3M+50.7% $112.4M+34.2% $83.7M-45.6% $154.0M+203.6% $50.7M-64.4% $142.6M+2.2% $139.5M
Investing Cash Flow -$33.7M+9.8% -$37.3M+17.9% -$45.5M+40.2% -$76.1M-23.0% -$61.9M+27.9% -$85.8M+64.0% -$238.4M-199.6% -$79.6M
Financing Cash Flow -$152.6M+32.7% -$226.9M-115.4% -$105.3M-38.8% -$75.9M+73.5% -$285.9M-1658.1% $18.3M-85.2% $123.6M+175.9% -$162.9M
Dividends Paid N/A N/A N/A N/A N/A N/A N/A N/A
Share Buybacks $93K-98.7% $7.4M-97.9% $353.1M+284683.9% $124K-98.6% $8.9M-4.7% $9.4M+6627.3% $139K+265.8% $38K

CRL Financial Ratios

Metric Q3'25 Q2'25 Q1'25 Q3'24 Q2'24 Q1'24 Q4'23 Q3'23
Gross Margin N/A N/A N/A 34.6%+0.1pp 34.5%+0.4pp 34.1% N/A 35.3%
Operating Margin 13.3%+3.6pp 9.7%+2.1pp 7.6%+24.3pp -16.7%-31.5pp 14.8%+2.3pp 12.4%-0.7pp 13.1%-1.6pp 14.8%
Net Margin 5.4%+0.3pp 5.1%+2.5pp 2.6%+24.0pp -21.4%-30.6pp 9.2%+2.0pp 7.2%-11.2pp 18.5%+9.9pp 8.5%
Return on Equity 1.6%+0.0pp 1.6%+0.8pp 0.8%-1.0pp 1.8%-0.7pp 2.5%+0.5pp 2.0%-3.2pp 5.2%+2.6pp 2.6%
Return on Assets 0.7%+0.0pp 0.7%+0.4pp 0.3%+3.2pp -2.9%-4.0pp 1.2%+0.3pp 0.9%-1.4pp 2.3%+1.1pp 1.1%
Current Ratio 1.370.0 1.36-0.1 1.43+0.0 1.41-0.2 1.58-0.2 1.75+0.2 1.52+0.1 1.45
Debt-to-Equity 0.64-0.1 0.70-0.1 0.79+0.1 0.650.0 0.65-0.1 0.730.0 0.74-0.0 0.76
FCF Margin 17.7%+1.3pp 16.4%+5.0pp 11.4%+3.1pp 8.3%-6.7pp 15.0%+10.0pp 5.0%-9.0pp 14.1%+0.5pp 13.6%

Similar Companies

Frequently Asked Questions

What is Charles Riv Labs Intl Inc's annual revenue?

Charles Riv Labs Intl Inc (CRL) reported $4.0B in total revenue for fiscal year 2024. This represents a -1.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Charles Riv Labs Intl Inc's revenue growing?

Charles Riv Labs Intl Inc (CRL) revenue declined by 1.9% year-over-year, from $4.1B to $4.0B in fiscal year 2024.

Is Charles Riv Labs Intl Inc profitable?

Yes, Charles Riv Labs Intl Inc (CRL) reported a net income of $22.2M in fiscal year 2024, with a net profit margin of 0.5%.

What is Charles Riv Labs Intl Inc's earnings per share (EPS)?

Charles Riv Labs Intl Inc (CRL) reported diluted earnings per share of $0.20 for fiscal year 2024. This represents a -97.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is Charles Riv Labs Intl Inc's EBITDA?

Charles Riv Labs Intl Inc (CRL) had EBITDA of $589.1M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Charles Riv Labs Intl Inc have?

As of fiscal year 2024, Charles Riv Labs Intl Inc (CRL) had $194.6M in cash and equivalents against $2.2B in long-term debt.

What is Charles Riv Labs Intl Inc's operating margin?

Charles Riv Labs Intl Inc (CRL) had an operating margin of 5.6% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.

What is Charles Riv Labs Intl Inc's net profit margin?

Charles Riv Labs Intl Inc (CRL) had a net profit margin of 0.5% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.

What is Charles Riv Labs Intl Inc's return on equity (ROE)?

Charles Riv Labs Intl Inc (CRL) has a return on equity of 0.6% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.

What is Charles Riv Labs Intl Inc's free cash flow?

Charles Riv Labs Intl Inc (CRL) generated $501.6M in free cash flow during fiscal year 2024. This represents a 37.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Charles Riv Labs Intl Inc's operating cash flow?

Charles Riv Labs Intl Inc (CRL) generated $734.6M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Charles Riv Labs Intl Inc's total assets?

Charles Riv Labs Intl Inc (CRL) had $7.5B in total assets as of fiscal year 2024, including both current and long-term assets.

What are Charles Riv Labs Intl Inc's capital expenditures?

Charles Riv Labs Intl Inc (CRL) invested $233.0M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

Does Charles Riv Labs Intl Inc buy back shares?

Yes, Charles Riv Labs Intl Inc (CRL) spent $119.2M on share buybacks during fiscal year 2024, returning capital to shareholders by reducing shares outstanding.

How many shares does Charles Riv Labs Intl Inc have outstanding?

Charles Riv Labs Intl Inc (CRL) had 51M shares outstanding as of fiscal year 2024.

What is Charles Riv Labs Intl Inc's current ratio?

Charles Riv Labs Intl Inc (CRL) had a current ratio of 1.41 as of fiscal year 2024, which is considered adequate.

What is Charles Riv Labs Intl Inc's debt-to-equity ratio?

Charles Riv Labs Intl Inc (CRL) had a debt-to-equity ratio of 0.65 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Charles Riv Labs Intl Inc's return on assets (ROA)?

Charles Riv Labs Intl Inc (CRL) had a return on assets of 0.3% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Charles Riv Labs Intl Inc's Altman Z-Score?

Charles Riv Labs Intl Inc (CRL) has an Altman Z-Score of 2.22, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Charles Riv Labs Intl Inc's Piotroski F-Score?

Charles Riv Labs Intl Inc (CRL) has a Piotroski F-Score of 6 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Charles Riv Labs Intl Inc's earnings high quality?

Charles Riv Labs Intl Inc (CRL) has an earnings quality ratio of 33.08x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Charles Riv Labs Intl Inc cover its interest payments?

Charles Riv Labs Intl Inc (CRL) has an interest coverage ratio of 1.8x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Charles Riv Labs Intl Inc?

Charles Riv Labs Intl Inc (CRL) scores 40 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.